RxDoctor Payments DataLook up a doctor →

Crystal Tuncay, DO

Internal Medicine · Valparaiso, INNPI 1992790414

Payments from drug & device makers

$32,947in general payments, 2019–2025

Across 913 payments — averaging $36.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$20K
  • Amgen$2K
  • AstraZeneca$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$665
  • Boehringer Ingelheim$575
  • plus $7K from 54 others

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)178$19,567
Amgen128$2,355
AstraZeneca60$1,730
Novo Nordisk96$1,241
Lilly USA, LLC37$665
Boehringer Ingelheim32$575
Bayer28$573
Astellas Pharma US Inc24$517
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC24$490
Merck35$447
Pfizer26$332
Novartis19$331
Otsuka America Pharmaceutical, Inc.18$305
Sanofi-aventis U.S. LLC17$279
Axsome Therapeutics, Inc.7$252
GSK16$236
Takeda Pharmaceuticals U.S.A., Inc.18$228
Amarin Pharma, Inc.16$215
Mylan Specialty L.p.9$184
IBSA Pharma Inc.10$180
Dexcom, Inc.11$158
Boston Scientific4$150
Heartflow, Inc.1$125
Vanda Pharmaceuticals Inc.5$122
Esperion Therapeutics, Inc.6$120
Phathom Pharmaceuticals, Inc.4$107
Exact Sciences6$106
Biohaven Pharmaceutical Holding Company Ltd.6$104
Vifor Pharma, Inc.5$101
Lundbeck LLC5$100
Idorsia Pharmaceuticals US Inc5$77
Radius Health, Inc.4$67
Insulet Corporation4$63
Ironwood Pharmaceuticals, Inc4$62
Regeneron Healthcare Solutions, Inc.3$59
Edwards Lifesciences3$57
Biohaven Pharmaceuticals, Inc.4$55
Alkermes, Inc.2$55
Xeris Pharmaceuticals, Inc.3$50
Otsuka Pharmaceutical Development & Commercialization, Inc.2$50
Arbor Pharmaceuticals, Inc.4$49
Abbott2$40
Johnson & Johnson3$37
Vivus LLC2$30
Tactile Systems Technology Inc1$28
Nevro Corp.1$27
Sumitomo Pharma America, Inc.1$23
Ultragenyx Pharmaceutical Inc.1$23
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)1$21
E.r. Squibb & Sons, L.L.C.1$18
Azurity Pharmaceuticals, Inc.1$17
Amneal Pharmaceuticals LLC1$17
Halozyme Inc1$16
Bausch Health US, LLC1$16
Alfasigma USA, Inc.1$15
Sanofi Pasteur Inc.1$15
Genentech USA, Inc.1$15
Teva Pharmaceuticals USA, Inc.1$14
Shire North American Group Inc1$13
Eisai Inc.1$12

How this compares

$32,947 in reported general payments places this provider in the 95th percentile of 1,747 internal medicine providers in Indiana.

See all internal medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$169,034
Medicare patients
373
Services billed
2,786

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Valparaiso

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →